NCT00307008View on ClinicalTrials.gov

Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population.

PHASE2CompletedINTERVENTIONAL
Enrollment

1,198

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

February 28, 2005

Study Completion Date

February 28, 2005

Conditions
Streptococcus Pneumoniae Vaccines
Interventions
BIOLOGICAL

Pneumovax 23™

Single dose intramuscular injection

Trial Locations (5)

SE-631 88

GSK Investigational Site, Eskilstuna

SE-551 85

GSK Investigational Site, Jönköping

SE-541 85

GSK Investigational Site, Skövde

SE-751 85

GSK Investigational Site, Uppsala

SE 721 89

GSK Investigational Site, Västerås

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00307008 - Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population. | Biotech Hunter | Biotech Hunter